Regulatory News:
Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026:
- 676 shares
- 1 173 521
Over the period from 01/01/2026 to 30/06/2026, a total of:
Number of executions | Number of shares | Traded volume in EUR | |
Buy side | 9,138 | 592,263 | 14,869,875.91 |
Sell side | 10,478 | 592,567 | 14,883,592.32 |
The following resources were included in the liquidity account at December 31, 2025:
- 980 shares
- 1 159 804
Following the reorganization within the Rothschild Co group and the transfer of Rothschild Co Martin Maurel's market-making activities to Rothschild Co Global Markets Solutions (Europe) SA, the latter has assumed management of the liquidity contract for Medincell [Euronext Paris FR0004065605] effective July 1, 2026. This transfer has no impact on the terms of the liquidity contract or on the resources allocated to its implementation, which are disclosed in the semiannual reports.
About Medincell
Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.
These treatments combine active pharmaceutical ingredients with our proprietary BEPO BEPO Star technologies, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable depot.
Risperidone LAI was the first treatment based on BEPO technology to receive FDA approval, initially for schizophrenia in April 2023, and subsequently for Bipolar I Disorder in October 2025. It is marketed in the United States by Teva under the brand name UZEDY. Medincell's risperidone LAI was also approved for schizophrenia in Canada and South Korea in 2025.
A New Drug Application (NDA) for Olanzapine LAI as a once-monthly treatment for schizophrenia in adults was submitted to the U.S. FDA in December 2025 by Medincell's partner, Teva. U.S. FDA accepted Teva's New NDA for Olanzapine LAI on February 20, 2026. A European Marketing Authorization Application (MAA) was also accepted by EMA in May 2026.
Medincell's investigational pipeline includes numerous innovative therapeutic candidates in various stages of development, from formulation to Phase 3 clinical trials. We collaborate with leading pharmaceutical companies and foundations to advance global health through new treatment options.
Headquartered in Montpellier, France, Medincell employs over 140 people representing more than 25 nationalities.
medincell.com
UZEDY is a trademark of Teva Pharmaceuticals. Medincell's BEPO technology is licensed to Teva as SteadyTeq, a trademark of Teva Pharmaceuticals.
This press release contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.
These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", "expect", "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "potential", "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's universal registration document, filed with the AMF on July 29, 2025, under number D. 25-0580 (the "Universal Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 30 et seq. 26 of the Registration Document.
Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.
This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions.
APPENDICES Rothschild Martin Maurel from 01/01/2026 to 30/06/2026
DATE | NB_ACHAT | NB_VENTE | QTE_ACHAT | QTE_VENTE | CAPITAUX_ACHETES | CAPITAUX_VENDUS |
02/01/2026 | 12 | 3 | 573 | 201 | 14 290,62 | 5 099,37 |
05/01/2026 | 68 | 57 | 2 715 | 1 567 | 66 028,80 | 38 375,83 |
06/01/2026 | 74 | 84 | 2 100 | 2 800 | 51 009,00 | 68 264,00 |
07/01/2026 | 88 | 162 | 1 500 | 3 300 | 36 990,00 | 81 840,00 |
08/01/2026 | 90 | 86 | 6 050 | 3 800 | 156 755,50 | 99 066,00 |
09/01/2026 | 77 | 94 | 3 857 | 3 107 | 99 356,32 | 80 626,65 |
12/01/2026 | 49 | 88 | 1 441 | 4 441 | 37 480,41 | 115 865,69 |
13/01/2026 | 72 | 208 | 5 000 | 4 000 | 132 300,00 | 105 560,00 |
14/01/2026 | 108 | 99 | 4 620 | 5 620 | 124 924,80 | 152 526,80 |
15/01/2026 | 168 | 130 | 8 907 | 3 907 | 242 982,96 | 105 449,93 |
16/01/2026 | 113 | 313 | 5 129 | 10 129 | 142 791,36 | 281 383,62 |
19/01/2026 | 36 | 13 | 2 251 | 651 | 61 925,01 | 18 175,92 |
20/01/2026 | 116 | 165 | 2 976 | 3 776 | 79 072,32 | 100 668,16 |
21/01/2026 | 81 | 70 | 3 253 | 4 053 | 87 505,70 | 109 795,77 |
22/01/2026 | 128 | 139 | 4 459 | 4 459 | 126 858,55 | 127 170,68 |
23/01/2026 | 77 | 39 | 3 113 | 3 113 | 89 311,97 | 89 561,01 |
26/01/2026 | 145 | 57 | 6 287 | 1 287 | 174 841,47 | 35 933,04 |
27/01/2026 | 63 | 180 | 4 030 | 5 930 | 110 099,60 | 162 066,90 |
28/01/2026 | 102 | 158 | 5 115 | 4 215 | 137 900,40 | 115 786,05 |
29/01/2026 | 174 | 132 | 4 980 | 2 180 | 117 229,20 | 51 709,60 |
30/01/2026 | 22 | 9 | 1 805 | 905 | 41 280,35 | 20 941,70 |
01/2026 | 1 863 | 2 286 | 80 161 | 73 441 | 2 130 934,34 | 1 965 866,72 |
02/02/2026 | 98 | 146 | 1 932 | 2 632 | 43 624,56 | 59 746,40 |
03/02/2026 | 57 | 116 | 7 500 | 8 000 | 174 075,00 | 185 760,00 |
04/02/2026 | 98 | 99 | 3 082 | 3 082 | 70 855,18 | 71 070,92 |
05/02/2026 | 68 | 163 | 1 271 | 2 271 | 29 360,10 | 52 982,43 |
06/02/2026 | 59 | 202 | 2 237 | 5 237 | 52 278,69 | 122 860,02 |
09/02/2026 | 62 | 122 | 1 356 | 3 056 | 32 747,40 | 73 802,40 |
10/02/2026 | 173 | 113 | 3 719 | 2 519 | 89 367,57 | 60 758,28 |
11/02/2026 | 231 | 376 | 4 530 | 5 780 | 105 322,50 | 136 234,60 |
12/02/2026 | 15 | 21 | 950 | 800 | 22 895,00 | 19 352,00 |
13/02/2026 | 55 | 119 | 1 350 | 2 250 | 32 589,00 | 54 877,50 |
16/02/2026 | 171 | 212 | 21 700 | 10 700 | 529 914,00 | 259 368,00 |
17/02/2026 | 66 | 382 | 1 482 | 12 482 | 35 894,04 | 305 309,72 |
18/02/2026 | 101 | 55 | 4 502 | 552 | 108 678,28 | 13 308,72 |
19/02/2026 | 155 | 106 | 2 569 | 3 801 | 62 195,49 | 92 212,26 |
20/02/2026 | 34 | 31 | 2 048 | 2 048 | 48 865,28 | 48 803,84 |
23/02/2026 | 284 | 314 | 12 851 | 15 040 | 310 737,18 | 364 569,60 |
24/02/2026 | 117 | 89 | 4 643 | 4 662 | 112 732,04 | 113 566,32 |
25/02/2026 | 90 | 72 | 3 060 | 3 570 | 74 541,60 | 87 143,70 |
26/02/2026 | 181 | 188 | 4 954 | 2 443 | 123 503,22 | 60 464,25 |
27/02/2026 | 122 | 67 | 4 406 | 3 815 | 103 541,00 | 89 805,10 |
02/2026 | 2 237 | 2 993 | 90 142 | 94 740 | 2 163 717,13 | 2 271 996,06 |
02/03/2026 | 127 | 129 | 3 032 | 3 032 | 69 645,04 | 70 160,48 |
03/03/2026 | 30 | 15 | 1 704 | 1 674 | 38 425,20 | 37 564,56 |
04/03/2026 | 32 | 99 | 1 006 | 3 635 | 22 363,38 | 84 113,90 |
05/03/2026 | 65 | 73 | 1 341 | 945 | 31 178,25 | 22 150,80 |
06/03/2026 | 47 | 39 | 3 403 | 3 403 | 74 321,52 | 74 423,61 |
09/03/2026 | 9 | 10 | 475 | 815 | 9 851,50 | 17 432,85 |
10/03/2026 | 136 | 109 | 2 839 | 2 939 | 63 621,99 | 66 009,94 |
11/03/2026 | 81 | 56 | 3 829 | 3 084 | 85 271,83 | 68 341,44 |
12/03/2026 | 32 | 22 | 1 387 | 2 030 | 29 598,58 | 43 178,10 |
13/03/2026 | 100 | 51 | 7 450 | 7 350 | 154 885,50 | 152 733,00 |
16/03/2026 | 72 | 31 | 6 523 | 6 523 | 135 547,94 | 135 678,40 |
17/03/2026 | 75 | 77 | 7 900 | 7 900 | 162 819,00 | 163 135,00 |
18/03/2026 | 114 | 67 | 17 539 | 17 539 | 365 863,54 | 365 688,15 |
19/03/2026 | 55 | 41 | 3 760 | 3 760 | 77 230,40 | 77 305,60 |
20/03/2026 | 46 | 31 | 3 756 | 3 104 | 77 411,16 | 64 097,60 |
23/03/2026 | 33 | 37 | 2 403 | 3 016 | 50 078,52 | 62 431,20 |
24/03/2026 | 60 | 43 | 3 755 | 3 755 | 79 643,55 | 79 643,55 |
25/03/2026 | 45 | 46 | 3 800 | 3 137 | 83 676,00 | 68 888,52 |
26/03/2026 | 42 | 30 | 2 902 | 2 902 | 62 799,28 | 62 973,40 |
27/03/2026 | 80 | 84 | 6 675 | 6 712 | 147 250,50 | 148 469,44 |
30/03/2026 | 67 | 53 | 3 821 | 3 922 | 83 832,74 | 86 127,12 |
31/03/2026 | 52 | 67 | 4 473 | 4 985 | 99 926,82 | 111 514,45 |
03/2026 | 1 400 | 1 210 | 93 773 | 96 162 | 2 005 242,24 | 2 062 061,11 |
01/04/2026 | 67 | 53 | 4 048 | 4 048 | 94 520,80 | 94 480,32 |
02/04/2026 | 50 | 38 | 3 492 | 3 487 | 79 617,60 | 79 538,47 |
07/04/2026 | 46 | 15 | 2 648 | 1 950 | 58 785,60 | 42 978,00 |
08/04/2026 | 47 | 42 | 3 600 | 3 676 | 81 612,00 | 83 114,36 |
09/04/2026 | 50 | 55 | 3 461 | 4 502 | 77 941,72 | 101 520,10 |
10/04/2026 | 51 | 36 | 4 189 | 2 585 | 99 195,52 | 61 135,25 |
13/04/2026 | 48 | 56 | 2 862 | 3 512 | 65 911,86 | 81 056,96 |
14/04/2026 | 38 | 54 | 2 365 | 3 193 | 56 665,40 | 76 376,56 |
15/04/2026 | 52 | 42 | 3 881 | 2 997 | 96 986,19 | 75 074,85 |
16/04/2026 | 72 | 57 | 4 272 | 3 069 | 103 083,36 | 73 932,21 |
17/04/2026 | 50 | 59 | 4 193 | 4 298 | 100 715,86 | 103 452,86 |
20/04/2026 | 57 | 50 | 3 834 | 3 926 | 90 827,46 | 92 928,42 |
21/04/2026 | 81 | 124 | 6 639 | 8 172 | 161 062,14 | 198 334,44 |
22/04/2026 | 46 | 41 | 3 300 | 3 300 | 80 949,00 | 81 147,00 |
23/04/2026 | 96 | 95 | 7 358 | 7 358 | 178 505,08 | 178 799,40 |
24/04/2026 | 45 | 28 | 3 670 | 1 994 | 86 612,00 | 47 118,22 |
27/04/2026 | 96 | 99 | 5 223 | 6 607 | 122 740,50 | 155 859,13 |
28/04/2026 | 52 | 21 | 3 374 | 1 728 | 78 411,76 | 40 176,00 |
29/04/2026 | 32 | 55 | 2 468 | 4 762 | 57 504,40 | 111 907,00 |
30/04/2026 | 45 | 39 | 3 176 | 3 275 | 76 986,24 | 79 451,50 |
04/2026 | 1 121 | 1 059 | 78 053 | 78 439 | 1 848 634,49 | 1 858 381,05 |
04/05/2026 | 77 | 71 | 5 918 | 5 730 | 142 387,08 | 138 551,40 |
05/05/2026 | 49 | 43 | 3 349 | 3 349 | 82 787,28 | 82 921,24 |
06/05/2026 | 50 | 41 | 6 600 | 4 391 | 175 362,00 | 116 405,41 |
07/05/2026 | 81 | 111 | 11 385 | 11 344 | 302 954,85 | 302 431,04 |
08/05/2026 | 64 | 59 | 7 824 | 7 789 | 203 815,20 | 203 137,12 |
11/05/2026 | 92 | 104 | 14 259 | 14 962 | 382 426,38 | 401 280,84 |
12/05/2026 | 72 | 122 | 9 608 | 10 540 | 257 974,80 | 284 053,00 |
13/05/2026 | 73 | 89 | 11 391 | 10 663 | 321 226,20 | 300 589,97 |
14/05/2026 | 42 | 54 | 5 148 | 6 289 | 143 989,56 | 176 469,34 |
15/05/2026 | 80 | 48 | 9 279 | 4 779 | 261 575,01 | 134 863,38 |
18/05/2026 | 43 | 39 | 3 465 | 2 865 | 92 654,10 | 76 638,75 |
19/05/2026 | 64 | 44 | 4 472 | 4 472 | 116 003,68 | 116 137,84 |
20/05/2026 | 18 | 74 | 2 072 | 6 287 | 55 674,64 | 169 497,52 |
21/05/2026 | 31 | 32 | 3 134 | 3 134 | 83 395,74 | 83 427,08 |
22/05/2026 | 90 | 75 | 12 451 | 12 451 | 336 550,53 | 337 795,63 |
25/05/2026 | 64 | 23 | 5 909 | 2 046 | 158 774,83 | 55 242,00 |
26/05/2026 | 43 | 60 | 3 599 | 3 599 | 95 841,37 | 95 913,35 |
27/05/2026 | 36 | 47 | 2 754 | 3 771 | 73 779,66 | 101 590,74 |
28/05/2026 | 15 | 50 | 1 249 | 3 711 | 34 097,70 | 103 351,35 |
29/05/2026 | 70 | 67 | 5 448 | 4 767 | 156 412,08 | 137 527,95 |
05/2026 | 1 154 | 1 253 | 129 314 | 126 939 | 3 477 682,69 | 3 417 824,95 |
01/06/2026 | 103 | 99 | 12 405 | 9 322 | 357 388,05 | 269 219,36 |
02/06/2026 | 65 | 52 | 5 454 | 3 189 | 150 639,48 | 87 729,39 |
03/06/2026 | 63 | 41 | 4 466 | 2 812 | 118 482,98 | 74 489,88 |
04/06/2026 | 26 | 24 | 1 900 | 1 900 | 49 780,00 | 49 875,00 |
05/06/2026 | 41 | 69 | 3 061 | 5 853 | 83 197,98 | 160 079,55 |
08/06/2026 | 52 | 129 | 4 260 | 10 463 | 117 576,00 | 290 034,36 |
09/06/2026 | 81 | 82 | 11 019 | 7 969 | 308 311,62 | 222 972,62 |
10/06/2026 | 94 | 40 | 7 055 | 4 017 | 189 708,95 | 108 097,47 |
11/06/2026 | 78 | 158 | 5 408 | 9 722 | 145 475,20 | 263 174,54 |
12/06/2026 | 53 | 69 | 4 680 | 4 345 | 128 512,80 | 119 791,65 |
15/06/2026 | 74 | 152 | 6 000 | 5 720 | 166 860,00 | 159 302,00 |
16/06/2026 | 95 | 167 | 12 764 | 15 301 | 358 923,68 | 430 876,16 |
17/06/2026 | 89 | 71 | 4 892 | 4 892 | 118 141,80 | 118 092,88 |
18/06/2026 | 137 | 150 | 11 990 | 9 981 | 300 709,20 | 250 722,72 |
19/06/2026 | 35 | 11 | 4 376 | 1 946 | 106 424,32 | 47 209,96 |
22/06/2026 | 48 | 93 | 4 296 | 6 311 | 105 896,40 | 156 007,92 |
23/06/2026 | 28 | 54 | 2 307 | 4 804 | 59 036,13 | 123 366,72 |
24/06/2026 | 45 | 26 | 3 547 | 1 452 | 89 916,45 | 36 387,12 |
25/06/2026 | 34 | 32 | 2 180 | 2 417 | 54 521,80 | 60 594,19 |
26/06/2026 | 42 | 45 | 2 550 | 2 730 | 65 713,50 | 70 406,70 |
29/06/2026 | 48 | 72 | 4 203 | 4 896 | 112 051,98 | 130 576,32 |
30/06/2026 | 32 | 41 | 2 007 | 2 804 | 56 396,70 | 78 455,92 |
06/2026 | 1 363 | 1 677 | 120 820 | 122 846 | 3 243 665,02 | 3 307 462,43 |
S1/2026 | 9 138 | 10 478 | 592 263 | 592 567 | 14 869 875,91 | 14 883 592,32 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260706818402/en/
Contacts:
David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com +33 (0)6 83 25 21 86
Grace Kim
Chief Strategy Officer, U.S. Finance
grace.kim@medincell.com +1 (646) 991-4023
Nicolas Mérigeau Gaëlle Fromaigeat
Media Relations
Medincell@newcap.eu +33 (0)1 44 71 94 94
Louis-Victor Delouvrier Alban Dufumier
Investor Relations France
Medincell@newcap.eu +33 (0)1 44 71 94 94
